Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II open label, non-randomized, dose escalation clinical trial assessing CG001419 in patients with advanced or metastatic solid tumors

Next Previous
Trial Profile

A Phase I/II open label, non-randomized, dose escalation clinical trial assessing CG001419 in patients with advanced or metastatic solid tumors

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CG 001419 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Cullgen

Most Recent Events

  • 27 Jul 2023 According to Cullgen media release, dosing has been initiated in this trial.
  • 18 Aug 2022 New trial record
  • 11 Aug 2022 According to Cullgen media release, the Chinese National Medical Products Administration (NMPA) has allowed the Investigational New Drug (IND) application for CG001419, a TRK degrader for the treatment of solid tumors

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top